Quantcast

Diabetes Market Value Exceeded USD 34 Bn in 2012, According to FirstWord Study Published at MarketPublishers.com

October 2, 2013

In-demand research study “Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight” worked out by FirstWord has been recently published by Market Publishers Ltd. According to the report, the diabetes market was valued at more than USD 34 billion as of 2012.

London, UK (PRWEB) October 03, 2013

During 2007-2012, the diabetes market experienced robust growth, recording a 10% CAGR. The rise in obesity, drug prices and disease prevalence has allowed diabetes drug sales to keep on outpacing big pharma drug sales. In 2012, the diabetes market was valued at more than USD 34 billion.

Sanofi’s insulin Lantus (insulin glargine) is the top-selling diabetes drug; it generated revenues of over USD 6.69 billion in 2012. The next best selling therapies were Merck’s dipeptidyl peptidase-IV (DPP-IV) Januvia (sitagliptin) (USD 4.1 billion), Novo Nordisk’s fast-acting insulin NovoRapid/NovoLog (insulin aspart) (USD 2.8 billion) and Eli Lilly’s Humalog (insulin lispro), another fast-acting insulin used for meal times (USD 2.4 billion). Insulin analogues represented the biggest class of therapies as of 2012, accounting for a market share of around 44% with revenues of just over USD 15 billion.

In-demand research study “Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight” worked out by FirstWord has been recently published by Market Publishers Ltd.

Report Details:

Title: Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight

Published: August, 2013

Price:    US$ 4,995.00

http://marketpublishers.com/report/diagnostics-diseases/diabetes/diabetes-battle-4-ascendancy-escalates-in-expanding-market-kol-insight.html

The report provides a comprehensive guide to the diabetes market. It contains a detailed disease profile, including vital information on diabetes’s epidemiology and aetiology, risk factors, symptoms, treatment and other relevant issues. The research study describes the actual state of the diabetes marketplace, reviews the current marketed therapies and pipeline therapies, and uncovers essential data on unmet needs in both type 1 and type 2 diabetes, and also identifies and analyzes the major factors, advances and trends which are currently influencing the diabetes treatment landscape. The report outlines prospects for the future development of the diabetes market, besides presenting the results of in-depth interviews with the five key opinion leaders (KOLs) from North America and seven KOLs from Europe.

Report Scope:

  •     Comprehensive analysis of the world diabetes market.
  •     Detailed disease profile.
  •     Description of the current market state and insights into the historical background of the industry.
  •     Review of the current therapies.
  •     Discussion of the unmet needs.
  •     Analysis of the major factors and trends influencing the market development.
  •     Future outlook for the diabetes market.
  •     Results of in-depth interviews with KOLs in diabetes treatment.

More insightful research reports by the publisher can be found at FirstWord page.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11190665.htm


Source: prweb



comments powered by Disqus